| (Values in U.S. Thousands) | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 | Sep, 2022 |
| Sales | 16,400 | 13,690 | 7,170 | 930 | 5,430 |
| Sales Growth | +19.80% | +90.93% | +670.97% | -82.87% | +1.31% |
| Net Income | -161,900 | -176,910 | -184,590 | -202,480 | -173,560 |
| Net Income Growth | +8.48% | +4.16% | +8.84% | -16.66% | +1.64% |
Mirati Therapeutics (MRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors.
Fiscal Year End Date: 12/31